{"id":759497,"date":"2023-05-18T07:08:16","date_gmt":"2023-05-18T11:08:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\/"},"modified":"2023-05-18T07:08:16","modified_gmt":"2023-05-18T11:08:16","slug":"gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\/","title":{"rendered":"Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference<\/b><\/p>\n<p>SAN DIEGO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nGossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced data from its Phase 2 TORREY Study of seralutinib in patients with PAH will be featured in two sessions at the American Thoracic Society 2023 International Conference taking place in Washington D.C. from May 19-24. Dr. Robert Frantz, Director of the Pulmonary Hypertension Clinic and Professor of Medicine at Mayo Clinic will present the data on behalf of the TORREY Study investigators.<\/p>\n<p><b>Session and Poster Details<\/b><\/p>\n<p><b>Session Title:<\/b> Breaking News: 2023 Clinical Trial Results in Pulmonary Medicine<br \/>\n<br \/><b>Date and Time: <\/b>Monday,<b \/>May 22, 2023, 9:04 AM EDT<br \/>\n<br \/><b>Session Location: <\/b>Walter E. Washington Convention Center, Ballroom C (Level 3)<br \/>\n<br \/><b>Presentation Title: <\/b>Seralutinib Treatment in Adult Subjects with Pulmonary Arterial Hypertension: Results from the TORREY Study<br \/>\n<br \/><b>Presenting Author: <\/b>Robert Frantz, M.D.<\/p>\n<p><b>Session Title:<\/b> Poster Discussion Session. D106. HOT OFF THE PRESSES! LATE BREAKERS IN PULMONARY VASCULAR DISEASE<br \/>\n<br \/><b>Date and Time: <\/b>Wednesday, May 24, 2023, 12:00 PM EDT<br \/>\n<br \/><b>Session Location:<\/b> Walter E. Washington Convention Center, Room 151 A (Street Level)<br \/>\n<br \/><b>Poster Title: <\/b>401 &#8211; Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results From the Phase 2 TORREY Trial<br \/>\n<br \/><b>Presenting Author: <\/b>Robert Frantz, M.D.<\/p>\n<p>\nThe presentation and poster will also be made available in the \u201cPosters and Publications\u201d section of the Gossamer Bio website at gossamerbio.com.<\/p>\n<p>\nFollowing the positive results observed in the TORREY study and discussions with worldwide regulatory authorities, Gossamer plans to initiate a registrational Phase 3 clinical trial in patients with PAH in the third quarter of 2023.<\/p>\n<p><b>About Gossamer Bio<\/b><\/p>\n<p>\nGossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients suffering from, pulmonary hypertension.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nGossamer cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company\u2019s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: the anticipated timing of initiation and enrollment of clinical trials for seralutinib, including the expected initiation of a Phase 3 clinical program for seralutinib. The inclusion of forward-looking statements should not be regarded as a representation by Gossamer that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Gossamer\u2019s business, including, without limitation: potential delays in the commencement, enrollment and completion of clinical trials; later developments with and \/ or feedback from global regulatory authorities or the FDA that may differ from prior feedback which may alter our planned Phase 3 clinical trial design and timing of initiation thereof; disruption to our operations from the COVID-19 pandemic, including clinical trial delays; the Company\u2019s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the results of preclinical studies and early clinical trials are not necessarily predictive of future results; the success of Gossamer\u2019s clinical trials and preclinical studies for seralutinib; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of seralutinib that may limit their development, regulatory approval and\/or commercialization, or may result in clinical holds, recalls or product liability claims; Gossamer\u2019s ability to obtain and maintain intellectual property protection for seralutinib; Gossamer\u2019s ability to comply with its obligations in collaboration agreements with third parties or the agreements under which it licenses intellectual property rights from third parties; unstable market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may adversely affect our business and financial condition and the broader economy and biotechnology industry; Gossamer may use its capital resources sooner than it expects; and other risks described in the Company\u2019s prior press releases and the Company\u2019s filings with the Securities and Exchange Commission (SEC), including under the heading \u201cRisk Factors\u201d in the Company\u2019s annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Gossamer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230518005332r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230518005332\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230518005332\/en\/<\/a><\/span><\/p>\n<p><b>For Investors and Media:<br \/>\n<\/b><br \/>Bryan Giraudo, Chief Operating Officer and Chief Financial Officer<br \/>\n<br \/>Gossamer Bio Investor Relations<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@gossamerbio.com\">ir@gossamerbio.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California District of Columbia United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Clinical Trials Research Pharmaceutical Science Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230518005332\/en\/818570\/3\/GossamerBio-Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference SAN DIEGO&#8211;(BUSINESS WIRE)&#8211; Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced data from its Phase 2 TORREY Study of seralutinib in patients with PAH will be featured in two sessions at the American Thoracic Society 2023 International Conference taking place in Washington D.C. from May 19-24. Dr. Robert Frantz, Director of the Pulmonary Hypertension Clinic and Professor of Medicine at Mayo Clinic will present the data on behalf of the TORREY Study investigators. Session and Poster Details Session Title: Breaking News: 2023 Clinical Trial Results in &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-759497","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference SAN DIEGO&#8211;(BUSINESS WIRE)&#8211; Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced data from its Phase 2 TORREY Study of seralutinib in patients with PAH will be featured in two sessions at the American Thoracic Society 2023 International Conference taking place in Washington D.C. from May 19-24. Dr. Robert Frantz, Director of the Pulmonary Hypertension Clinic and Professor of Medicine at Mayo Clinic will present the data on behalf of the TORREY Study investigators. Session and Poster Details Session Title: Breaking News: 2023 Clinical Trial Results in &hellip; Continue reading &quot;Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-18T11:08:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230518005332r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference\",\"datePublished\":\"2023-05-18T11:08:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\\\/\"},\"wordCount\":839,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230518005332r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\\\/\",\"name\":\"Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230518005332r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-05-18T11:08:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230518005332r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230518005332r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\/","og_locale":"en_US","og_type":"article","og_title":"Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference - Market Newsdesk","og_description":"Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference SAN DIEGO&#8211;(BUSINESS WIRE)&#8211; Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced data from its Phase 2 TORREY Study of seralutinib in patients with PAH will be featured in two sessions at the American Thoracic Society 2023 International Conference taking place in Washington D.C. from May 19-24. Dr. Robert Frantz, Director of the Pulmonary Hypertension Clinic and Professor of Medicine at Mayo Clinic will present the data on behalf of the TORREY Study investigators. Session and Poster Details Session Title: Breaking News: 2023 Clinical Trial Results in &hellip; Continue reading \"Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-18T11:08:16+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230518005332r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference","datePublished":"2023-05-18T11:08:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\/"},"wordCount":839,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230518005332r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\/","name":"Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230518005332r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-05-18T11:08:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230518005332r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230518005332r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gossamer-bio-announces-torrey-data-to-be-featured-at-american-thoracic-society-2023-international-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/759497","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=759497"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/759497\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=759497"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=759497"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=759497"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}